FDA Hands Boston Scientific Warning Letter For Clinical Trial Violations
This article was originally published in The Gray Sheet
A recent bioresearch monitoring 1warning letter to Boston Scientific, sent Aug. 30, is unrelated to an outstanding corporate-wide letter issued to the firm in 2006 - but the two letters, taken together, could make life harder for the company
You may also be interested in...
Boston Scientific's recent resolution of a warning letter pertaining to quality control deficiencies at one of its cardiac rhythm management device manufacturing plants should help increase sales of the implants in the coming quarters, the firm says
FDA is targeting Boston Scientific with a rare and far-reaching enforcement measure that could prevent some of the firm's investigational products from receiving market approval in the near term
Boston Scientific intends to acquire carotid stent manufacturer EndoTex by year-end, following an anticipated FDA approval of NexStent